Mutations of IDH2 are frequently observed in acute myeloid leukaemia [41], colon cancer [42, 43], and gliomas [44], causing alterations in metabolism and DNA methylation; these mutations could represent a possible mechanism of tumorigenesis [44] and provide potential avenues for therapeutic intervention. This evidence concerns the gene IDH2 and central nervous system cancer.